These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9718211)

  • 1. Macromolecular organisation of recombinant Yersinia pestis F1 antigen and the effect of structure on immunogenicity.
    Miller J; Williamson ED; Lakey JH; Pearce MJ; Jones SM; Titball RW
    FEMS Immunol Med Microbiol; 1998 Jul; 21(3):213-21. PubMed ID: 9718211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles.
    Sabhnani L; Manocha M; Sridevi K; Shashikiran D; Rayanade R; Rao DN
    FEMS Immunol Med Microbiol; 2003 Oct; 38(3):215-29. PubMed ID: 14522457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.
    Goodin JL; Nellis DF; Powell BS; Vyas VV; Enama JT; Wang LC; Clark PK; Giardina SL; Adamovicz JJ; Michiel DF
    Protein Expr Purif; 2007 May; 53(1):63-79. PubMed ID: 17293124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge.
    Andrews GP; Heath DG; Anderson GW; Welkos SL; Friedlander AM
    Infect Immun; 1996 Jun; 64(6):2180-7. PubMed ID: 8675324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague.
    Williamson ED; Packer PJ; Waters EL; Simpson AJ; Dyer D; Hartings J; Twenhafel N; Pitt ML
    Vaccine; 2011 Jun; 29(29-30):4771-7. PubMed ID: 21570437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clone expression of the caf1 gene of Yersinia pestis and immunological evaluation on recombinant F1 antigen].
    Wang P; Shi GX; Wang HB; Yu DZ; Zhang JZ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Jan; 31(1):69-72. PubMed ID: 20302703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.
    Leary SE; Griffin KF; Garmory HS; Williamson ED; Titball RW
    Microb Pathog; 1997 Sep; 23(3):167-79. PubMed ID: 9281474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new purification strategy for fraction 1 capsular antigen and its efficacy against Yersinia pestis virulent strain challenge.
    Wang T; Qi Z; Wu B; Zhu Z; Yang Y; Cui B; Dai R; Zhang Q; Qiu Y; Wang Z; Wang H; Guo Z; Wang X; Yang R
    Protein Expr Purif; 2008 Sep; 61(1):7-12. PubMed ID: 18539482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant capsular antigen (fraction 1) from Yersinia pestis induces a protective antibody response in BALB/c mice.
    Simpson WJ; Thomas RE; Schwan TG
    Am J Trop Med Hyg; 1990 Oct; 43(4):389-96. PubMed ID: 2240367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yersinia pestis Yop secretion protein F: purification, characterization, and protective efficacy against bubonic plague.
    Swietnicki W; Powell BS; Goodin J
    Protein Expr Purif; 2005 Jul; 42(1):166-72. PubMed ID: 15939303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates.
    Williamson ED; Flick-Smith HC; Waters E; Miller J; Hodgson I; Le Butt CS; Hill J
    Microb Pathog; 2007 Jan; 42(1):11-21. PubMed ID: 17107769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
    Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
    Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of a recombinant form of the V antigen of Yersinia pestis, using three different expression systems.
    Carr S; Miller J; Leary SE; Bennett AM; Ho A; Williamson ED
    Vaccine; 1999 Aug; 18(1-2):153-9. PubMed ID: 10501245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
    Eyles JE; Butcher WA; Titball RW; Hill J
    Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV.
    DeBord KL; Anderson DM; Marketon MM; Overheim KA; DePaolo RW; Ciletti NA; Jabri B; Schneewind O
    Infect Immun; 2006 Aug; 74(8):4910-4. PubMed ID: 16861680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague.
    Levy Y; Flashner Y; Tidhar A; Zauberman A; Aftalion M; Lazar S; Gur D; Shafferman A; Mamroud E
    Vaccine; 2011 Sep; 29(40):6866-73. PubMed ID: 21803090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates.
    Mizel SB; Graff AH; Sriranganathan N; Ervin S; Lees CJ; Lively MO; Hantgan RR; Thomas MJ; Wood J; Bell B
    Clin Vaccine Immunol; 2009 Jan; 16(1):21-8. PubMed ID: 18987167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yersinia outer proteins (YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a murine model of bubonic plague.
    Leary SE; Griffin KF; Galyov EE; Hewer J; Williamson ED; Holmström A; Forsberg A; Titball RW
    Microb Pathog; 1999 Mar; 26(3):159-69. PubMed ID: 10089156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis.
    Honko AN; Sriranganathan N; Lees CJ; Mizel SB
    Infect Immun; 2006 Feb; 74(2):1113-20. PubMed ID: 16428759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
    Gupta G; Khan AA; Rao DN
    Scand J Immunol; 2010 Mar; 71(3):186-98. PubMed ID: 20415784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.